The FDA granted cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) approval for treatment of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
FEBRUARY 17, 2021